Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors

Sk. Abdul Amin a, Suvankar Banerjee a, Kalyan Ghosh b, Shovanlal Gayen b,*, Tarun Jha a,*

a Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, P. O. Box 17020, Jadavpur University, Kolkata 700032, India
b Laboratory of Drug Design and Discovery, Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, MP, India

A R T I C L E   I N F O

Keywords:
COVID-19
SARS-CoV-2
Mpro
PLpro
Non-covalent inhibitor
Structure-activity relationship (SAR)

A B S T R A C T

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brutally perils physical and mental health worldwide. Unavailability of effective anti-viral drug rendering global threat of COVID-19 caused by SARS-CoV-2. In this scenario, viral protease enzymes are crucial targets for drug discovery. This extensive study meticulously focused on two viral proteases such as main protease (Mpro) and papain-like protease (PLpro), those are essential for viral replication. This review provides a detail overview of the targets (Mpro and PLpro) from a structural and medicinal chemistry point of view, together with recently reported protease inhibitors. An insight into the challenges in the development of effective as well as drug like protease inhibitors is discussed. Peptidomimetic and/or covalent coronavirus protease inhibitors possessed potent and selective active site inhibition but compromised in pharmacokinetic parameters to be a drug/drug like molecule. Lead optimization of non-peptidomimetic and/or low molecular weight compounds may be a better option for oral delivery. A masterly combination of adequate pharmacokinetic properties with coronavirus protease activity as well as selectivity will provide potential drug candidates in future. This study is a part of our endeavors which surely dictates medicinal chemistry efforts to discover effective anti-viral agent for this devastating disease.

1. Introduction

In late December 2019, the newly emerged highly contagious novel coronavirus disease 2019 (COVID-19) was identified in Humans.1,2 The outburst of virus containing a single positive-stranded RNA first found to occur in Wuhan, China and was named as severe acute respiratory syndrome (SARS-CoV-2) (SARS-CoV-2).3-11 Worldwide more than millions of cases have been registered.11 According to World Health Organization (WHO), the highly transmissible disease COVID-19 has so far, more than millions confirmed cases and deaths have been reported from 216 countries around the globe.12

Currently, this virus is far more contagious and more catastrophic compared to other flu-viruses with several symptoms like fever, cough, pneumonia, nausea, and fatigue.13 Hence, the World Health Organization was forced to declare a state of global health emergency to organized scientific and medical efforts to quickly develop a cure for patients.14 Presently, there is no specific targeted therapy against this novel virus. Thus, the scientific community is making great efforts to explore diverse mechanisms to restrict the virus replication. As a result, diverse antiviral drugs with similar viral infections were tested on patients. Several drugs like: Remdesivir (designed for the Ebola virus),14 Lopinavir/Ritonavir (designed for the HIV),15 chloroquine and hydroxychloroquine (designed for anti-malarial action)16 and Tocilizumab (designed for rheumatoid arthritis)10 were found to be effective against this deadly virus, but their efficacy still remains controversial.17

The current impact of COVID-19 outbreak and the possibility of forthcoming CoV epidemics prove that there is a need for rapid discovery of anti-COVID-19 drugs. Recent studies revealed that SARS-CoV-
2 has a comparable genomic pattern to other corona viruses. These viruses mainly comprises of a 5′-untranslated region (UTR), a replicase complex for encoding non-structural proteins (nsps), spike protein (S) gene, envelope protein (E), membrane protein (M) gene, nucleocapsid protein (N) gene, 3′-UTR, and numerous unknown non-structural parts which provide them support against the environmental factors. Usually, these viruses harvest several polypeptides which promote proteolytic breakdown to produce 20 additional proteins during their lifecycle. Among them two crucial proteases such as main protease (Mpro) and papain-like protease (PLpro) are vital for virus repli lifecycle. Among these the two proteases, the coronavirus Main protease (Mpro) also recognized as 3C like protease (3CLpro) acknowledged great attention for its significant role in enzymatic activity leading to its post-translational processing of replicate polyproteins. The Mpro consist of 306 amino acid long and has high structural and sequence resemblance to that of SARS-CoV Mpro. SARS-CoV-2 Mpro monomer comprises of three domains (i.e., N-terminal domain-I, N-terminal domain-II, and C-terminal domain-III). The Mpro active site consists of two catalytic dyad C145 and H41 (Fig. 1A–B).

On the other hand, papain-like protease (PLpro) active site consists of catalytic triad (Fig. 1C–D). PLpro functions by cleaving ISG15, a two-domain Ub-like protein, and Lys48-linked polyUb chains. Hence, their main function lies in the processing of the viral polypeptide into functional proteins, which further deubiquitinize and dampen host anti-viral reactions by hijacking the ubiquitin (Ub) enzyme playing the pivotal role in host defense mechanism. Therefore, the two proteases are equally important for viral lifecycle and are supported by several studies which reveal that most of the coronaviridae genome encropts two polyproteins, pp1a and pp1ab during their translation stage through ribosomal frame shifting mechanism. These polyproteins were further processed into mature non-structural proteins (nsps) by Mpro and PLpro which plays a vital role in the transcription/replication. Targeting these may hence institute a valid tactic for antiviral drug design and discovery.

In the 21st century, drug repurposing, screening of databases and designing different inhibitors are the only fastest possibility in terms drug discovery to prevent the catastrophe caused by COVID-19 outbreak. Diverse approaches have also been made in order to get insights into the mechanism of these proteases and to inhibit their functions but still there has been a lot of groundwork to be done for drug discovery and development against these targets. This study, as a part of rational drug design and discovery, aims to sketch out the current status of SARS-CoV-2 protease inhibitors based drug discovery. We also try to provide a new insight into coronavirus protease structural biology and discuss the challenges in the development of effective as well as drug like protease inhibitors. The study will offer an initiative to stimulate further research by providing useful guidance to the medicinal chemists for designing of new protease inhibitors effective against COVID-19 in near future.

2. Structural biology of SARS-CoV-2 proteases

CoV is a single-stranded positive sense RNA virus where genome is encapsulated within a membrane envelope. The spike glycoprotein of CoV regulates its entry into the host cells. Two polyproteins (pp1a and pp1ab) are translated after virion entry into the host cells, which are promptly split by two viral proteases including Mpro and PLpro. Further proteolytic cleavage of these two viral polyproteins resulted in sixteen non-structural proteins (nsp1 to nsp16). The PLpro manages the proteolytic cleaving of nsp 1–3, whereas all junctions downstream of nsp4 are cleaved by Mpro.

The Mpro cleaves at no fewer than 11 sites on the large polyprotein 1ab with the recognition sequence of L-Q↓ (S, A, G) (↓ refers the cleavage site). The Mpro of SARS-CoV-2 is a 67.6 kDa homodimeric cysteine protease having huge sequence identity with SARS-CoV Mpro (Fig. 1). Mpro of CoV forms a dimer where each monomer consists of N-terminal catalytic region and the C-terminal region. Moreover, the N-terminal residues form a typical chymotrypsin fold while the C-terminal residues form an extra domain. In addition, each protomer containing three domains such as domains I (residues 8–101), II (residues 102–184) and domain III (residues 201–303). Domains I and II espouses a double β-barrel fold and the active site is located in a shallow cleft between two antiparallel β-barrels (Fig. 1). Notably, C terminal helical-bundle domain, Domain III, might involve in stabilization of their active homodimer forms. The active site can be further divided into several (sub)sites. Notably, the catalytic dyad formed by H41-C145 is observed at the S1 site (Fig. 2). The hydrophobic side chains are found mostly at the S2 and S4 sites. The list of amino acid residues play key role in SARS-CoV-2 Mpro is highlighted in Table 1.

---

**Fig. 1.** Three-dimensional structures of (A) SARS-CoV Mpro (PDB: 3ATW), (B) SARS-CoV-2 Mpro (PDB: 6LU7), (C) SARS-CoV PLpro (PDB: 4OW0), (D) SARS-CoV-2 PLpro (PDB: 6WUU). The amino acids formed catalytic dyad for Mpro and catalytic triad for PLpro are also highlighted.
threatens public health globally. In its infancy, little knowledge about the exact molecular mechanisms of the disease is obstructing the attempts to develop promising anti-viral drugs. Hence, bioinformatics and molecular modeling approaches are the only handy strategy until precise molecular and structural biology is known.

FDA-approved drugs surely claim safe alternatives if it exhibits at least modest activity against SARS-CoV-2. Currently, scientific community are largely focused in the screening of – (i) FDA-approved drug databases, (ii) clinical trials molecules and/or (iii) previously reported coronavirus inhibitors. In silico virtual screening (VS) techniques are proficient to explore CoV protease inhibitors.47–49 Yu and co-workers reported the computational screening and findings with regard to potential binding luteolin and other natural compounds against Mpro. Notably, luteolin has also been found to bind effectively with other targets (PLpro, Spike protein, and RdRp) of SARS-CoV-2.60–62

Vast amount of in silico VS studies against SARS-CoV-2 Mpro has been reported over past months.63–66 As the detailed description on the molecular modeling studies is out of Scope for this current communication, readers interested in learning more about recent molecular modeling studies to identify probable CoV protease inhibitors are directed to mentioned references66,68 and others.

Since the SARS-CoV-2 Mpro shares about 96% sequence similarity with SARS-CoV Mpro, previously reported SARS-CoV Mpro inhibitors may have huge prospect to show their efficacy against SARS-CoV-2 Mpro also. By May this year, we have endorsed our rational anti-viral drug design efforts through data mining and molecular docking studies.10 In an endeavour, our research team explored the crucial structural fingerprints modulating SARS-CoV-PLpro inhibitory activities by the aid of 2D-QSAR, SPCI analysis as well as Monte Carlo optimization based QSAR. Further, QSAR derived virtual screening of some in-house molecules were done which rendered some important hits.

3. Search of protease inhibitors against COVID-19

3.1. Molecular modeling and in silico virtual screening against SARS-CoV-2

Table 2

| Role in SARS-CoV-2 PLpro | Residue |
|-------------------------|--------|
| Catalytic triad          | C111, H272, D286 |
| Substrate binding        | Y268, M208, P247, P248, T301, P248, Y264, N267, Q269, L162, C270, G271 and Y273 |

Since the sequences of SARS-CoV-2 and SARS-CoV Mpro share 96% of identity and the minimum differences between both enzymes resides at the surface of the proteins. Therefore, inhibitors against SARS-CoV-Mpro are expected to inhibit SARS-CoV-2 Mpro.

The ligand-bound X-ray structure of SARS-CoV-2 PLpro was elucidated few days ago.7 A close comparisons of apo SARS-CoV-2 PLpro (PDB: 6W9C) to inhibitor-bound SARS-CoV-2 PLpro (PDB: 6WUU and 6WX4) possessed similar overall structures with little exception of the β14–6WX4) possessed similar overall structures with little exception of the catalytic C111 of SARS-CoV-2 PLpro engages in Michael addition to the warhead of inhibitors and rendering the formation of a covalent thio-ether linkage.

The list of amino acid residues play key role in SARS-CoV-2 PLpro is highlighted in Table 2.

Notably, SARS-CoV-2 PLpro and SARS-CoV PLpro only differ by 54 residues.24 The residues of active site are almost identical. Moreover, the PLpro of SARS-CoV-2 and SARS-CoV demonstrated an almost comparable architecture of S4–S2 site suggesting comparable substrate preference.

Table 1

| Role in SARS-CoV-2 Mpro | Residue |
|-------------------------|--------|
| Catalytic dyad          | H41, C145 |
| Substrate binding       | H41, M49, G143, S144, H163, H164, M165, E166, L167, D187, R188, Q189, T190, A191, Q192 |
| Dimerization            | R4, S10, G11, E14, N28, S139, F140, S147, E290, R298 |

The residues of active site are almost identical. Moreover, the PLpro of SARS-CoV-2 and SARS-CoV demonstrated an almost comparable architecture of S4–S2 site suggesting comparable substrate preference.

Fig. 2. SARS-CoV-2 (A) Mpro and (B) PLpro binding sites.

3.2. What efforts are taken to identify COVID-19 protease inhibitors?

In February 2020, the first crystal structure of SARS-CoV-2 virus Mpro (PDB: 6LU7) with covalent inhibitor N3 (Fig. 3) was reported by Jin and co-workers.3

The isobutyl function of N3 embed itself in the hydrophobic S2 site formed by H41, M49, and M169 (Fig. 3A–B). This study forms the basis of rapid target-based discovery of lead molecules against 2019-nCoV Mpro.

After that lot of target-based virtual screening were performed to find out promising protease inhibitors against COVID-19. Jin et al screened more than 10,000 molecules underwent SARS-CoV-2 Mpro structure-based virtual and high-throughput screening, which finally identified six small-molecule inhibitors including two FDA-approved drugs (Disulfiram and Carmofur) and clinical trials compounds
Bioorganic & Medicinal Chemistry 29 (2021) 115860

(Ebselen, Tideglusib, Shikonin and PX-12) with an IC50 range of 0.67–21.4 μM (Fig. 3). Notably, Ebselen (SARS-CoV-2 Mpro IC50 = 0.67 μM) showed promising anti-viral activity in cell-based assays (EC50 = 4.67 μM).

Su and co-workers elucidated the SARS-CoV-2 Mpro crystal structure in complex with a non-covalent, non-peptidomimetic inhibitor baicalein (Fig. 5) at a resolution of 2.2 Å (PDB: 6M2N). Interestingly, baicalein is snugly fitted in the core of the substrate-binding site by interacting catalytic oxyanion loop (residues 138–145), E166, those are critical not only for recognition of substrates but also peptidomimetic inhibitors. Nevertheless, baicalein revealed a unique binding mode in comparison with other covalent or peptidomimetic inhibitors.

A comparison analysis of the inhibitor-bound CoV Mpro crystal structures suggested that a peptidomimetic inhibitor portrayed like a ‘sword’, while baicalein set a ‘shield’ near the two catalytic dyads to restrict the binding of the substrate. In addition, baicalein was also found promising in an enzymatic assay against SARS-CoV-2 Mpro (IC50 = 0.94 μM). It also exhibited a dose-dependent inhibition on the replication of SARS-CoV-2 with a half-maximal effective concentrations (EC50 = 1.69 μM). The unique binding mode and promising ligand-binding efficiency of baicalein will inspire Researchers for further lead optimization.

Fig. 3. Structure of SARS-CoV-2 Mpro inhibitors.

Fig. 4. (A) Binding modes of SARS-CoV-2 Mpro inhibitors (N3, GC-376, 13b, 11a and 11b) at the active site, (B) Interaction of GC-376 with the amino acid residues, (C) Binding modes of SARS-CoV-2 PLpro inhibitors (VIR250 and VIR251) at the active site, (D) Interaction of VIR250 with the amino acid residues at active site of SARS-CoV-2 PLpro.
Ma et al. employed a fluorescence resonance energy transfer (FRET)-
based SARS-CoV-2 Mpro enzymatic assay to explore a library of known
protease inhibitors. Among these, four inhibitors such as boceprevir
(HCV NS3/4A protease inhibitor, SARS-CoV-2 Mpro IC\textsubscript{50} = 4.13 μM),
GC-376 (calpain protease inhibitor, SARS-CoV-2 Mpro IC\textsubscript{50} = 0.030 μM),
calpain inhibitors II (SARS-CoV-2 Mpro IC\textsubscript{50} = 0.97 μM) and XII
(SARS-CoV-2 Mpro IC\textsubscript{50} = 0.45 μM) exhibited promising SARS-CoV-2
Mpro inhibitory activities (Fig. 5).

Structure-based design, synthesis and activity assessment by Zhang
et al. facilitated the development of peptidomimetic a-ketoamides as
broad-spectrum inhibitors of beta coronavirus and alpha coronavirus
Mpro. The most potent compound 11r of this series displayed EC\textsubscript{50} of
400 pM against MERS-CoV in virus-infected Huh7 cells (Fig. 6). Notably,
11r exhibited broad-spectrum anti-viral activity due to its P2 cyclohexyl
moiety which intended to fit the pocket in the enterovirus Mpro.

In another study, the same group modified the chemical structure of
11r by replacing the hydrophobic cinnamoyl moiety by comparatively
less hydrophobic Boc group and concealing the
P2 cyclohexyl moiety of
11r with cyclopropyl resulted an increase in the anti-viral prop-
yectivity against SARS-CoV-2 Mpro (13b: IC\textsubscript{50} = 0.67 μM, Fig. 6). This
molecule 13b also showed potency against Mpro of SARS-CoV (IC\textsubscript{50} =
0.90 μM) and MERS-CoV (IC\textsubscript{50} = 0.58 μM). Furthermore, the X-ray
crystal structure of 13b-bound SARS-CoV-2 Mpro conferred that the
carbonyl oxygen of pyridone in the P3-P2 position formed hydrogen
bond with the main-chain amide of E166. Despite the protecting Boc
group on P3 unable to occupy the canonical S4 site of Mpro the protease,
it was found at close enough to P168 and subsequently, directed out-
ward by more than 2 Å relative to apo-Mpro structure of SARS-CoV-2.
Further removal of Boc group in compound 14b (Fig. 6) led to fall in
the inhibitory action, suggesting that hydrophobicity and bulkiness of
Boc group would be important to cross the cellular membrane.

Dai et al. elucidated two crystal structures of SARS-CoV-2 Mpro in
complex with two indole based covalent inhibitors (Fig. 6) at a high
resolution. The indole ring of 11a at P3 occupied the solvent exposed
S4 site to form a 2.6-Å hydrogen bond with E166 along with hydro-
phobic interactions with side chains of residues P168 and Q189. Since
the S2 site of CoV Mpro withholds bulky P2 fragment, the cyclohexyl
moiety of 11a is buried snugly into the S2 pocket of SARS-CoV-2 Mpro
and stacking with the imidazole ring of H41. It also interacts with the
side chains of M49, Y54, M165, D187 and R188. In contrast, fluophenyl
function of 11b at P2 undergoes a significant downward rotation and
form additional hydrogen bond Q189 that is likely to enhance Mpro
inhibitory activity. Notably, the aldehyde functions of both 11a and 11b
act as a warhead in P1 to form a covalent bond with cysteine residue.
Moreover, the (S)-γ-lactam ring immerses into the S1 site of CoV Mpro
to form several hydrogen bonds with H163, F140 and E166. Both of these
inhibitors displayed excellent Mpro inhibitory activities (11a: SARS-
CoV-2 Mpro IC\textsubscript{50} = 0.053 μM; 11b: SARS-CoV-2 Mpro IC\textsubscript{50} =
0.040 μM) along with good PK properties in vivo. Hence, from the above
studies, it may be observed that S2 site in SARS-CoV-2 Mpro can
be occupied a broad range of hydrophobic substitutions. The isobutyl,
cyclopropyl, cyclohexyl and 3-FPh moieties of inhibitors embed themselves
in the hydrophobic S2 site formed by H41, M49, and M169.

Despite huge research efforts on SARS-CoV-2 Mpro inhibitors, pro-
teomic and structural biology works on SARS-CoV-2 PLpro and its

---

**Fig. 5.** Structure of SARS-CoV-2 Mpro inhibitors namely Baicalin, Baicalein, Boceprevir, GC-376, calpain inhibitors II and XII.
Fig. 6. Structure of SARS-CoV-2 Mpro inhibitors (11r, 13a, 13b, 14b, 11a and 11b).

Fig. 7. Structure of SARS-CoV-2 PLpro inhibitors (VIR250 and VIR251) and naphthyl based SARS-CoV-2 PLpro inhibitors.
inhibitor have been very few. Nevertheless, Rut and co-workers utilised HyCoSuL (Hybrid Combinatorial Substrate Library) to scrutinize substrate specificity of SARS-CoV-2 PLpro enzymes. Two irreversible inhibitors namely VIR250 and VIR251 having high degree of PLpro selectivity over other proteases were identified (Fig. 7). The same study first time reported the inhibitor-bound crystal structures of SARS-CoV-2 PLpro. Altogether, these crystal structures in complex with VIR250 (PDB: 6WUU) and VIR251 (PDB: 6WX4) provide a basic for rapid rational drug design against SARS-CoV-2 PLpro. 

We have reported the SARs and QSAR of naphthalene based SARS-CoV PLpro inhibitors. Very recently, Freitas and co-workers reported these naphthalene based derivatives against SARS-CoV-2 PLpro and SARS-CoV-2 replication. Since the residues in the BL2 loop of PLpro are almost identical between SARS-CoV-2 and SARS-CoV-1, this probably facilitated the binding of naphthalene based derivatives. GRL-0617 (IC₅₀ of 2.4 μM and 600 nM against SARS-CoV-2 PLpro and SARS-CoV-1 PLpro, respectively) and compound 6 (IC₅₀ of 5 μM and 2.6 μM against SARS-CoV-2 PLpro and SARS-CoV-1 PLpro, respectively) exhibited excellent potency against SARS-CoV-2 replication (Fig 7). In addition, the lead compounds, 77247723 and 6577871 exhibited IC₅₀ values of 23.5 μM and 100.7 μM, respectively against SARS-CoV-2 PLpro. Previously they (77247723 and 6577871) displayed IC₅₀ values of 20 μM and 59 μM, respectively against SARS-CoV-2 PLpro IC₅₀ Values, respectively. Therefore, it may be postulated that previously designed naphthalene based SARS-CoV PLpro inhibitors follows the similar trend of structure–activity relationship against SARS-CoV-2 PLpro also.

3.3. Challenges in drug discovery efforts for SARS-CoV-2 protease inhibitors

The corona virus protease inhibitors discovery effort targeting Mpro and PLpro have presenting a substantial challenge owing to poor pharmacokinetic properties of peptidomimetic/macromolecular compounds and low inhibitory potency of non-peptidomimetic and/or compounds having low molecular weight. To be an effective drug/drug candidate, a molecule must have ability not only to reach its desire target in the body in sufficient concentration but also to possess expected biological responses. Drug discovery and development markedly depends on assessment of absorption, distribution, metabolism and excretion (ADME) characteristics. Notably, the macromolecule approach of developing SARS-CoV-2 Mpro as well as PLpro inhibitors has been advantageous over the low molecular weight compounds in terms of inhibitory potency and selectivity. In fact the former can occupy the different parts of the active sites of the Mpro and PLpro enzyme to manifest potential inhibitory property. We have collected recently published different SARS-CoV-2 Mpro inhibitors and analyzed for their drug likeliness and other physicochemical properties. From the analysis we have seen that most of these compounds fail to pass the drug-likeness

Fig. 8. (A) Radar plot of four prototype compounds N3, 13b, Disulfiram, Carmofur after calculating ADME data (http://www.swissadme.ch/) suggesting the drug-likeness. Pink area represents the optimal range of each property. LIPO = Lipophilicity, SIZE = Molecular weight, POLAR = Polarity, INSOLU = Solubility, INSATU = Saturation, FLEX = Flexibility; (B) Correlation of SARS-CoV-2 Mpro inhibitory activity with eleven molecular descriptors (N = 25); (C) The correlation matrix of the physic-chemical and structural properties along with SARS-CoV-2 Mpro pIC₅₀ (N = 25) at significant p-statics; (D) The correlation matrix of the ADME properties along with SARS-CoV-2 Mpro pIC₅₀ (N = 25) at significant p-statics.
Molecules including Baicalein, Disulfiram, Carmofur (Fig. 8A), Ebselen, Tideglibus, Shikonin and PX-12 coherently passed the drug likeness to be suitable drug but adding challenge to achieve potency and selectivity against coronavirus protease. A similar trend is seen with the endpoint from Table 3 which was calculated to frisk the linear relationships. However, the similar analysis has not been possible for the SARS-CoV-2 PLpro inhibitors due to the insufficient number of reported compounds. The correlation of SARS-CoV-2 Mpro inhibitory activity with eleven molecular descriptors (N = 25) at significant p-statistics is graphically represented in Fig. 8B. A positive coefficient of the eight descriptors referred to the favourable effect on the SARS-CoV-2 Mpro inhibitory potential of the studied compounds, while the negative coefficient of three descriptors, i.e., Fraction Csp3, WLOGP, MLOGP, exhibited detrimental effect on the inhibitory properties. The correlation matrix of the physico-chemical and structural properties along with SARS-CoV-2 Mpro pIC50 (N = 25) at significant p-statistics is depicted in Fig. 8C.

Commonly, among these 25 derivatives, several molecules carrying hydrogen bond donor (HBD) > 3 and total polar surface area (TPSA) > 150 were poorly active. Besides, molecules with TPSA < 90 and HBD < 3 frequently possessed lower Mpro inhibitory potency. Regarding the influence of lipophilicity in Mpro activity, highly hydrophobic (WLOGP > 2.9 and MLOGP > 1.6) derivatives were ill-active against Mpro. Interestingly, in this dataset, the least active compound namely cinanserin possessed a lower molecular weight (MW = 340.48), lesser hydrogen bond donor (HBD) and acceptor (HBA) groups (HBD = 1 and HBA = 2), lower total polar surface area (TPSA = 57.64) as well as high hydrophobic nature (WLOGP = 4.08 and MLOGP = 3.76) compared to the most potent Mpro inhibitor (GC-376: MW = 507.53, HBD = 4, HBA = 8, TPSA = 182.34, WLOGP = 0.75 and MLOGP = -0.08).

Moreover, from the properties such as, blood–brain-barrier permeability (BBB permeant), inhibition capability of CYP1A2 (CYP1A2 inhibitor), CYP2C19 (CYP2C19 inhibitor) as well as permeability coefficient (log Kp (cm/s)) of these molecules can be negatively correlated with their Mpro inhibitory potency (Fig. 8D). Noticeably, most of this dataset molecule with a log Kp (cm/s) value ≥ −6.0 exhibited lesser to-poorly active nature against Mpro. Hence, this should be addressed in Mpro and PLpro protease-based drug discovery which could help harness the therapeutic potential against COVID-19.

4. Conclusion and future perspective

COVID-19 disease is few months old. Until precise molecular and structural biology underlying SARS-CoV-2 replication are available, bioinformatics and multi-target molecular modeling driven in vitro antiviral study as well as repurposing of previous SARS-CoV protease inhibitors are the handy strategies. From the SARs, it may be postulated that peptidomimetic and/or covalent coronavirus protease inhibitors possessed potent and selective active-site inhibition. However, these inhibitors exhibited poor absorption, distribution, metabolism, and excretion as well as toxicity parameters to be a drug/drug like molecule. Consequently, repurposing/new protease inhibitors discovery efforts of peptidomimetic compounds have presenting a substantial challenge owing to poor pharmacokinetic properties. On the other hand, non-peptidomimetic and/or compounds having low molecular weight coherently passed the drug likeness to be suitable drug but adding challenge to achieve potency and selectivity against coronavirus protease. Hence, lead optimization of non-peptidomimetic and/or low molecular weight compounds should be focused. In this scenario, fragment based drug design (FBDD) approaches can play a significant role in designing and developing potential protease inhibitors. The effective strategy for drug discovery of potential protease inhibitors may consist of following steps: step 1: identification of low molecular weight compounds as protease inhibitors; step 2: identification of good fragments from peptidomimetic compounds by different experimental and computational methods; step 3: incorporating of good fragments during the lead optimization of the low molecular weight compounds; step 4: final optimization of these hybrid molecules for satisfactory pharmacokinetic and pharmacodynamics properties. A masterly combination of adequate pharmacokinetic properties with coronavirus protease activity as well as selectivity will provide strong drug candidates in future.

Based on recent mechanistic and structural data on other viral proteases including HIV, we can anticipate or rather suggest to target the allosteric sites of coronavirus proteases as strategies-based drug discovery. This effort may soon emerge as frontiers in SARS-CoV-2 Mpro and PLpro drug discovery to triumph the battle against COVID-19.

### Table 3

| Entry | Name | SARS-CoV-2 Mpro IC50 (µM) | pIC50 |
|-------|------|--------------------------|-------|
| 1     | N3   | –                        | –     |
| 2     | Ebselen | 0.67                     | 6.174 |
| 3     | Disulfiram | 9.35                     | 5.029 |
| 4     | Tideglibus | 1.55                     | 5.810 |
| 5     | Carmofur | 1.82                     | 5.740 |
| 6     | Shikonin | 15.75                    | 4.803 |
| 7     | PX-12  | 21.39                    | 4.670 |
| 8     | Cinanerin | 124.93                   | 3.903 |
| 9     | 11a   | 0.053                    | 7.276 |
| 10    | 11b   | 0.04                     | 7.398 |
| 11    | 11r   | 0.18                     | 6.745 |
| 12    | 13a   | 2.39                     | 6.522 |
| 13    | 13b   | 0.67                     | 6.174 |
| 14    | 14b   | –                        | –     |
| 15    | Simprevir | 12.74                    | 4.862 |
| 16    | Boceprevir | 4.13                     | 5.384 |
| 17    | Narlaprevir | 5.73                     | 5.242 |
| 18    | MG-132 | 3.9                      | 5.409 |
| 19    | Calpeptin | 10.69                    | 4.971 |
| 20    | Calpain inhibitor III | >20                      | –     |
| 21    | Calpain inhibitor IV | >20                     | –     |
| 22    | Calpain inhibitor I (ALLN) | 8.6                     | 5.066 |
| 23    | MG-115 | 3.14                     | 5.503 |
| 24    | Calpain inhibitor II (ALLM) | 0.97                  | 6.013 |
| 25    | Calpain inhibitor XII | 0.45                    | 6.347 |
| 26    | PSE  | 10.38                    | 4.984 |
| 27    | GC-376 | 0.03                     | 7.523 |
| 28    | Rupintrivir | >20                   | –     |
| 29    | Camostat | >20                     | –     |
| 30    | Lopinavir | >20                     | –     |
| 31    | Ritonavir | >20                   | –     |
| 32    | Bicaflavin | 6.41                    | 5.193 |
| 33    | Baicalein | 0.94                    | 6.027 |

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Acknowledgment**

Financial assistance from the Council of Scientific and Industrial Research (CSIR), New Delhi, India in the form of a Senior Research Fellowship (SRF) [FILE NO.: 09/096(0967)/2019-EMR-I, Dated: 01-04-2019] to Sk. Abdul Amin is thankfully acknowledged. Suvankar Banejee and Tarun Jha are thankful for the financial support from RUSA 2.0 of UGC, New Delhi, India to Jadavpur University, Kolkata, India. We are very much thankful to the Department of Pharmaceutical Technology,
Jadavpur University, Kolkata, India and Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, India for providing the research facilities.

References

1. Zuma A, Chan JP, Ashar EI, Hui DS, Yuen KY. Coronavirus–drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:337.

2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.

3. Jin Z, Du X, Xu Y, et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020;585:289–293.

4. Zhang L, Lin D, Kosov Y, et al. A-koetamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. Chem Med Chem. 2020;6:456–4578.

5. Ghosh AK, Brindisi M, Shahabi D, Chapman ME, Meszar M. Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics. MedChemChem. 2020;15:907–922.

6. Gil C, Giner T, Masero L, et al. COVID-19: Drug targets and potential treatments. J Med Chem. 2020. https://doi.org/10.1021/acs.jmedchem.0c00606.

7. Rut W, Lz V, Zmudzinski M, et al. Activity profiling and structures of inhibitor-bound SARS-CoV-2-3CLpro protease provides a framework for anti-COVID-19 drug design. BioRxiv. 2020. https://doi.org/10.1101/2020.04.26.088990.

8. Su H, Yao S, Zhao W, Li M, Liu J, Shang W. Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro. BioRes. 2020. https://doi.org/10.1101/2020.04.13.038687.

9. Amin SA, Jha T. Fight against novel coronavirus: a perspective of medicinal chemists. Eur J Med Chem. 2020;201, 112559.

10. Amin SA, Ghosh K, Gayen S, Jha T. Chemical-informatics approach to COVID-19 drug discovery: Exploration of important fragments and data mining prediction of some hits from natural origins as main protease (Mpro) inhibitors. J Mol Struct. 2020. https://doi.org/10.1016/j.ijms.2020.1780946.

11. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19, 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the Media-briefing-on-covid-19 (accessed 13 October 2020).

12. https://www.who.int/emergencies/diseases/COVID-19-2020 (accessed 13 October 2020).

13. Hsi H, HS F. A. HF. A. Science. 2009;323:376–380.

14. Ma C, Sacco MD, Hurst B, et al. Boceprevir, GC-376, and calpain inhibitors II, XII, and X as broad-spectrum inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): an in-silico evidence on direct interaction. J Mol Struct. 2020;13:327–345.

15. Letko M, Zamaratski JA, AAP. Papain-Like proteases as coronaviral drug targets: Current Inhibitors, opportunities, and limitations. Pharmaceuticals (Basel). 2020;13: 1277–1301.

16. Khanal RA, Saadfar M, Ozaran M. Genomic characterization of a novel SARS-CoV-2 Gene. Rev. 2020, 16, 100682.

17. Yu R, Chen L, Lan R, Ren L, Li P. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Int J Antimicrob Agents. 2020;61, 105912.

18. Zhou Y, Hou Y, Shen J, Huang Y, Martin C, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Dev. 2020;6:1–8.

19. Perman S, Nieland J. Coronavirus: progression of JOB updates on replication and pathogenesis. Nat Rev Microbiol. 2020;18, 439–450.

20. Shang Y, Ge Y, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;1–4.

21. Lan J, Je J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain in complex with the ACE2 receptor. Nature. 2020;1–6.

22. Lotz M, Marzini A, Munster V. Functional assay of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5: 562–569.

23. Biesz-Santos YM, John SE, Meszar D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21–38.

24. Jiménez-Alberto A, Ribas-Aparicio RM, Aparicio-Orozco G, Castellán-Vega JA. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors. J Mol Biol. 2020;513:1–20.

25. Kumar V, Roy K. Development of a simple, interpretable and easily transferrable scoring model for quick screening of approved drugs in search of novel 3CL protease (3CLpro) enzyme inhibitors against SARS-CoV-2 diseases. SAR QSAR Environ Res. 2020;1–16. https://doi.org/10.1080/1062936X.2020.1776388.

26. Havranek B, Islam SM. An in silico approach for identification of novel inhibitors as potential therapeutic candidates for COVID-19. J Biomol Struct Dom. 2020;201, 1776158.

27. Gao K, Nguyen DD, Chen J, Wang R, Wei G. Re-positioning of 8565 existing drugs for COVID-19. J Phys Chem Lett. 2020. https://doi.org/10.1021/acs.jpclett.0c00179.

28. Ng ST, QuynhAnh Pham N, Th Le L, Pham DH, Yu VV. Computational determination of potential inhibitors of SARS-CoV-2 main protease. J Chem Inf Model. 2020. https://doi.org/10.1021/acs.jcim.0c00491.

29. Wang J. Fast Identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model. 2020. https://doi.org/10.1021/acs.jcim.0c00179.

30. Wang R, Hozumi Y, Yin C, Wei G. Deducing SARS-CoV-2 transmission, evolution and ramifications on COVID-19 diagnosis, vaccine, and medicine. J Chem Inf Model. 2020. https://doi.org/10.1021/acs.jcim.0c00559.

31. Al-Khafaji K, Al-Dahdahawi LD, TaskinToK T. Using Integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. J Biomol Struct Dom. 2020. https://doi.org/10.1080/1062936X.2020.1764392.

32. Reiner Z, Hatamipoor MW, Banach M, et al. STAT5 and the COVID-19 main protease in silico evidence on direct interaction. Arch Med Sci. 2020;16:490–496.

33. Bhadravaj VK, Singh R, Sharma J, Rajendran V, Purohit R, Kumar S. Identification of bioactive molecules from Tea plant as SARS-CoV-2 main protease inhibitors. J Biomol Struct Dom. 2020;1–3. https://doi.org/10.1080/1062936X.2020.1766572.

34. Joshi T, Joshi T, Sharma P, et al. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking. Eur Rev Med Pharmacol Sci. 2020;24:4529–4536.

35. Choudhary C. Fragment tailoring strategy to design novel chemical entities as potential binders of novel coronavirus main protease. J Biomol Struct Dom. 2020. https://doi.org/10.1080/1062936X.2020.1771424.

36. Amin SA, Mohammad T, Ansari S, et al. Glycopeptides and Masaribo are high-affinity inhibitors of SARS-CoV-2 main protease: Possible therapeutic implication in COVID-19.
69 Calligari P, Bobone S, Ricci G, Bocedi A. Molecular investigation of SARS-CoV-2 main protease 3CLpro of the COVID-19 via structure-based ligand design and large-scale structure-activity relationship analysis. J Infect Pharmacol. 2020;5:224.

70 Han Z, Chen X, Li X, et al. Peptide-like and small-molecule inhibitors of SARS-CoV-2 main protease 3CLpro. J Biomol Struct Dyn. 2020. https://doi.org/10.1080/07391102.2020.1757150.

71 Chen YW, Yu CP, Bong KY. Prediction of the SARS-CoV-2 3C-like protease (3CL) structure: virtual screening reveals velpatasvir, lopinavir, and other drug repurposing candidates [version 1; peer review: 3 approved] FI0002 Rev 2020/9/129. DOI: 10.12668/fix0002research.224571.

72 Zhang DH, Wu KL, Zhang X, Deng SQ, Peng B. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus J Inorg Biochem. 2020;181:152–158.

73 Qamar MTul, Alqahthani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020. https://doi.org/10.1016/j.jpha.2020.03.009.

74 Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19: drug repurposing approach. Life Sci. 2020;252, 117652.

75 Hall Jr DC, JI HF. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020. https://doi.org/10.1016/j.tmaid.2020.101466.